Rafferty Asset Management LLC Buys 199,990 Shares of ImmunityBio, Inc. $IBRX

Rafferty Asset Management LLC raised its stake in ImmunityBio, Inc. (NASDAQ:IBRX) by 79.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 452,458 shares of the company’s stock after purchasing an additional 199,990 shares during the period. Rafferty Asset Management LLC’s holdings in ImmunityBio were worth $1,113,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. AQR Capital Management LLC grew its position in shares of ImmunityBio by 193.4% in the 1st quarter. AQR Capital Management LLC now owns 44,448 shares of the company’s stock worth $134,000 after buying an additional 29,297 shares during the last quarter. Rathbones Group PLC boosted its stake in ImmunityBio by 21.5% in the second quarter. Rathbones Group PLC now owns 117,420 shares of the company’s stock valued at $310,000 after acquiring an additional 20,800 shares in the last quarter. Summit X LLC acquired a new position in shares of ImmunityBio during the second quarter worth $28,000. ProShare Advisors LLC lifted its holdings in shares of ImmunityBio by 21.4% during the 2nd quarter. ProShare Advisors LLC now owns 80,128 shares of the company’s stock valued at $212,000 after purchasing an additional 14,105 shares during the last quarter. Finally, SBI Securities Co. Ltd. boosted its position in shares of ImmunityBio by 824.1% in the 2nd quarter. SBI Securities Co. Ltd. now owns 118,069 shares of the company’s stock worth $312,000 after purchasing an additional 105,292 shares in the last quarter. 8.58% of the stock is currently owned by institutional investors.

ImmunityBio Stock Down 3.2%

Shares of IBRX opened at $8.67 on Friday. ImmunityBio, Inc. has a 52 week low of $1.83 and a 52 week high of $12.43. The company has a market capitalization of $8.91 billion, a price-to-earnings ratio of -22.82 and a beta of -0.03. The stock’s 50-day moving average price is $6.00 and its 200-day moving average price is $3.61.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. The company had revenue of $38.29 million during the quarter. As a group, equities analysts anticipate that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

Insider Transactions at ImmunityBio

In other news, Director Barry J. Simon sold 165,000 shares of the stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $10.25, for a total transaction of $1,691,250.00. Following the sale, the director directly owned 2,925,821 shares of the company’s stock, valued at $29,989,665.25. This represents a 5.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Christobel Selecky sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $5.00, for a total value of $250,000.00. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 501,967 shares of company stock valued at $4,466,412. Insiders own 69.48% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. The Goldman Sachs Group reiterated a “buy” rating on shares of ImmunityBio in a research note on Monday, February 23rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. Jefferies Financial Group upped their price target on shares of ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Friday, December 12th. HC Wainwright raised their price target on shares of ImmunityBio from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, February 23rd. Finally, D. Boral Capital reiterated a “buy” rating and set a $23.00 price objective on shares of ImmunityBio in a research note on Monday, February 23rd. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $13.60.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.